IMS MAXIMS Launches Software to Support Dementia Challenge

IMS MAXIMSIMS MAXIMS, a supplier of end-to-end electronic patient record systems, has launched software designed specifically to support NHS trusts with early diagnosis and improved care of patients with dementia. The MAXIMS Dementia System has been developed to meet the increasing demand from NHS organisations for a solution that not only prompts healthcare professionals to make relevant assessments for people with suspected dementia but one that also guides them to the correct care pathway to ensure that they receive the most appropriate referral and treatment.

Dementia affects an estimated 670,000 people in England alone, with this figure expected to double in the next 30 years. This is already resulting in more than 25% of general hospital beds at any one time being occupied by patients who have been diagnosed with dementia.

As part of the government's drive to ensure patients are diagnosed as early as possible and treated in the correct care setting, the Department of Health has introduced a Commissioning for Quality Innovation (CQUIN) payment framework, which incentivises the identification of patients with dementia as well as prompting appropriate referral and follow up. In addition to this, as of April 2013, the framework will be extended further to show how quality dementia care is being delivered.

Shane Tickell, CEO of IMS MAXIMS, said: "The misdiagnosis and delayed or incorrect treatment of long term conditions such a dementia is placing a huge strain on our NHS, with dementia estimated to cost our society in excess of £19 billion per year.

"IMS MAXIMS recognises the increasing need for trusts to manage the identification and referral process of dementia patients. Our aim is to help trusts capture data as easily and effectively as possible to improve the identification, and quality of care of dementia patients and receive the correct payments for doing so."

The IMS MAXIMS dementia software has been developed based on NICE guidelines and by working in partnership with NHS organisations aiming to improve their patient care pathways. The software, which integrates with virtually any system, takes users step-by-step through each of the CQUIN target's three stages (Find, Assess & Investigate, Review (FAIR)) allowing trusts to easily collate data ready for extraction. It can also be tailored so that clinical users establish a simple workflow, identifying dementia symptoms and other cognitive impairments early, resulting in more accurate referrals to the appropriate diagnostic assessment, treatment and support.

A dementia record is created for each patient who meets criteria set within the CQUIN framework; clinical users then follow a simple work-list within the software to complete the FAIR process:

  • Find - using the software's Confusion Assessment Screening, users can identify whether patients have delirium or dementia within 72 hours of admittance;
  • Assess & Investigate - conducting an Abbreviated Mental Test Score, investigate other potential diagnosis (clinical notes can be created and User Defined Assessments enabled to support FAIR process);
  • Referral - specialist diagnostic advice and follow up means healthcare professionals can direct patients, their carers and families to the correct services and support they need.

Currently only around 42% of people with dementia in England have a formal diagnosis. IMS MAXIMS software not only automatically directs clinical users through the FAIR process helping to reduce this figure, but also assists in identifying other causes and diagnosis of cognitive impairment, leading to reduced lengths of stay, improved efficiency of discharges, fewer readmissions and inter-ward transfers.

Tickell added: "IMS MAXIMS is committed to developing systems that support the increasing and ever changing challenges that the NHS faces. Working within the CQUIN framework has allowed us to develop software, which helps trusts become more efficient in administrative terms whilst improving patient well-being and care. We look forward to continuing to work alongside healthcare organisations to provide the most advanced IT solutions possible to address the issues they face."

About IMS MAXIMS
IMS MAXIMS is an electronic patient record provider working towards better, safer patient care. Specialists in developing clinical and administrative software solutions for healthcare providers, IMS MAXIMS currently supports more than 150 organisations, 11 million patient records in the UK, and 1.9 million patient records in Ireland, approx 50% of the population, as well as 20,000 users of IMS MAXIMS products.

MAXIMS is at the heart of the clinical and administrative life of everything from large UK and Irish hospitals, to small specialist independent clinics. It gives patient data to clinicians in exactly the format they need, and allows it to be shared with colleagues and updated in real-time. MAXIMS suits any clinical specialism and is excellent for order communications and reporting. Medical and administrative records can be kept fully up to date, with minimum effort. MAXIMS is web-based so there is no need to install software on computers or invest in expensive extra hardware.

Most Popular Now

New App may Help Caregivers of People Ge…

A new study by investigators from Mass General Brigham showed that a new app they created can help improve the quality of life for caregivers of patients undergoing bone marrow...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...